Medical Senology Research Unit & Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy.
Breast. 2012 Oct;21(5):621-8. doi: 10.1016/j.breast.2012.06.003. Epub 2012 Jun 29.
To develop a Risk Score (RS) to predict distant recurrence among premenopausal women with node-negative endocrine-responsive early breast cancer.
The Cox model was used to develop the RS using clinical and histopathological features from 378 women participating in the IBCSG Trial VIII who received endocrine therapy alone or following chemotherapy. The performance of the resulting model was validated on a cohort of 1005 patients from a single institution who received endocrine therapy alone.
In a multivariable analysis, the risk of distant recurrence was associated with tumor size, ER, Ki-67 and peritumoral vascular invasion. In the validation cohort, patients with high RS were at greater risk of distant recurrence compared to patients with low RS (HR, 17.41; 95% CI, 5.72-52.95).
In premenopausal women with node-negative endocrine-responsive early breast cancer, the RS identifies patients at higher risk of distant recurrence.
开发一种风险评分（RS），以预测无淋巴结转移的内分泌反应性早期乳腺癌的绝经前女性的远处复发。
采用 Cox 模型，利用 378 名接受内分泌治疗或化疗联合内分泌治疗的 IBCSG 试验 VIII 参与者的临床和组织病理学特征，开发了该 RS。在接受内分泌治疗的单一机构的 1005 名患者队列中对该模型进行了验证。
多变量分析中，远处复发的风险与肿瘤大小、ER、Ki-67 和肿瘤周围血管侵犯有关。在验证队列中，高 RS 患者的远处复发风险高于低 RS 患者（HR，17.41；95%CI，5.72-52.95）。
在无淋巴结转移的内分泌反应性早期乳腺癌的绝经前女性中，RS 可识别出远处复发风险较高的患者。
